Clinical Trial

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Advanced Liver Cancer

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
Single-arm, open-label, interventional study evaluating adoptive cell therapy (ACT) with autologous tumor-infiltrating lymphocytes (TIL) infusion followed by IL-2 after a non-myeloablative(NMA) lymphodepletion preparative regimen for the treatment of patients with advanced liver cancer.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-10-09.
Trial Details
NCT Number NCT06084299
Lead Sponsor Zhiyong Huang
Collaborators: Wuhan Elongevity Technology Co., Ltd.
Conditions Liver Cancer
Enrollment 16 participants
Start Date 2020-05-27
Primary Completion 2026-08-30 (estimated)
Study Completion 2026-08-30 (estimated)
Updated on ClinicalTrials.gov 2025-08-19